Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 213,927
  • Shares Outstanding, K 25,620
  • Annual Sales, $ 13,260 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 2.79
  • Price/Sales 16.42
  • Price/Cash Flow 0.00
  • Price/Book 2.96

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.10 +3.09%
on 08/15/17
13.05 -36.02%
on 07/27/17
-1.15 (-12.11%)
since 07/14/17
3-Month
6.00 +39.17%
on 05/17/17
13.05 -36.02%
on 07/27/17
+2.10 (+33.60%)
since 05/16/17
52-Week
4.50 +85.56%
on 11/03/16
13.05 -36.02%
on 07/27/17
+1.21 (+16.95%)
since 08/16/16

Most Recent Stories

More News
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

SPPI : 9.50 (+1.28%)
SMMT : 12.53 (+0.24%)
IMDZ : 8.35 (-1.76%)
ECYT : 1.31 (-0.76%)
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

SMMT : 12.53 (+0.24%)
IMDZ : 8.35 (-1.76%)
ECYT : 1.31 (-0.76%)
SHPG : 148.44 (+0.49%)
Immune Design In Shares Up 43.9% Since SmarTrend's Buy Recommendation (IMDZ)

SmarTrend identified an Uptrend for Immune Design In (AMEX:IMDZ) on May 19th, 2017 at $7.13. In approximately 3 months, Immune Design In has returned 43.86% as of today's recent price of $10.25.

IMDZ : 8.35 (-1.76%)
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

MRK : 62.70 (+0.32%)
IMDZ : 8.35 (-1.76%)
RHHBY : 31.5400 (+0.03%)
SNY : 48.43 (+1.25%)
Immune Design (IMDZ) Looks Good: Stock Adds 7% in Session

Immune Design Corp. (IMDZ) shares rose 7% in the last trading session.

IMDZ : 8.35 (-1.76%)
CSRMY : 15.0000 (+10.18%)
What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?

Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.

IMDZ : 8.35 (-1.76%)
TSRO : 112.99 (-0.89%)
RHHBY : 31.5400 (+0.03%)
PFE : 33.36 (-0.06%)
Immune Design In Up 63.5% Since SmarTrend Uptrend Call (IMDZ)

SmarTrend identified an Uptrend for Immune Design In (AMEX:IMDZ) on May 19th, 2017 at $7.13. In approximately 2 months, Immune Design In has returned 63.51% as of today's recent price of $11.65.

IMDZ : 8.35 (-1.76%)
Immune Design In Has Returned 32.6% Since SmarTrend Recommendation (IMDZ)

SmarTrend identified an Uptrend for Immune Design In (AMEX:IMDZ) on May 19th, 2017 at $7.13. In approximately 2 months, Immune Design In has returned 32.63% as of today's recent price of $9.45.

IMDZ : 8.35 (-1.76%)
Shares of IMDZ Up 40.4% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Immune Design In (AMEX:IMDZ) on May 19th, 2017 at $7.13. In approximately 1 month, Immune Design In has returned 40.35% as of today's recent price of $10.00.

IMDZ : 8.35 (-1.76%)
Immune Design (IMDZ) Shows Strength: Stock Moves 6.2% Higher

Immune Design Corp. (IMDZ) shares rose a little above 6% in the last trading session.

AERI : 52.20 (-0.38%)
IMDZ : 8.35 (-1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Support & Resistance

2nd Resistance Point 9.08
1st Resistance Point 8.71
Last Price 8.35
1st Support Level 8.12
2nd Support Level 7.90

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.